Lutz Jacobasch
Dresden, SN, Germany
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 26 publications
Chemotherapy for patients with circulating tumour DNA-positive, stage II colon cancer (CIRCULATE)-an AIO/ABCSG trial.
Journal: Annals of oncology : official journal of the European Society for Medical Oncology
Published: March 20, 2026
Erratum: Benefit of Chemoradiotherapy Versus Chemotherapy After Induction Therapy for Conversion of Unresectable Into Resectable Pancreatic Cancer: The Randomized CONKO-007 Trial.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: January 08, 2026
Pirtobrutinib Versus Ibrutinib in Treatment-Naïve and Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: December 07, 2025
Benefit of Chemoradiotherapy Versus Chemotherapy After Induction Therapy for Conversion of Unresectable Into Resectable Pancreatic Cancer: The Randomized CONKO-007 Trial.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: August 13, 2025
Predictive criteria for overall survival and treatment duration of 2nd-line chemotherapy in patients with advanced pancreatic adenocarcinoma (AIO-PAK-0216).
Journal: British journal of cancer
Published: March 24, 2025
Final Results From a Large, Non-Interventional, Phase 4 Study of Ruxolitinib for the Treatment of Myelofibrosis in Clinical Routine.
Journal: European journal of haematology
Published: February 25, 2025
Prospective validation of the modified metastatic colorectal cancer score (mCCS) in >600 patients with RAS-wild-type metastatic colorectal cancer treated with first-line panitumumab plus FOLFIRI/FOLFOX: Final results of the non-interventional study VALIDATE.
Journal: International journal of cancer
Published: January 28, 2025
End Point Surrogacy in First-Line Chronic Lymphocytic Leukemia.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: August 30, 2024
Inflammatory Stress Determines the Need for Chemotherapy in Patients with HER2-Positive Esophagogastric Adenocarcinoma Receiving Targeted Therapy and Immunotherapy.
Journal: Cancer immunology research
Published: June 15, 2024
Nanoliposomal Irinotecan With Fluorouracil and Leucovorin or Gemcitabine Plus Cisplatin in Advanced Cholangiocarcinoma: A Phase II Study of the AIO Hepatobiliary-YMO Cancer Groups (NIFE-AIO-YMO HEP-0315).
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: June 06, 2024
Nanoliposomal irinotecan and fluorouracil plus leucovorin versus fluorouracil plus leucovorin in patients with cholangiocarcinoma and gallbladder carcinoma previously treated with gemcitabine-based therapies (AIO NALIRICC): a multicentre, open-label, randomised, phase 2 trial.
Journal: The lancet. Gastroenterology & hepatology
Published: February 16, 2024
Real-world analysis of ruxolitinib in myelofibrosis: interim results focusing on patients who were naïve to JAK inhibitor therapy treated within the JAKoMo non-interventional, phase IV trial.
Journal: Annals of hematology
Published: July 28, 2023
Last Updated: 09/26/2026